Re­im­burse­ment be­gins slow­ly for Bio­gen’s ex­pen­sive Alzheimer’s drug

Medicare Ad­min­is­tra­tive Con­trac­tors, or MACs, are now spo­rad­i­cal­ly re­im­burs­ing for Bio­gen’s ex­pen­sive new Alzheimer’s drug in lim­it­ed pock­ets across the US, as CMS has sev­er­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.